» Articles » PMID: 35581350

Retinoic Acid Signaling Acts As a Rheostat to Balance Treg Function

Abstract

Regulatory T cells (Tregs) promote immune homeostasis by maintaining self-tolerance and regulating inflammatory responses. Under certain inflammatory conditions, Tregs can lose their lineage stability and function. Previous studies have reported that ex vivo exposure to retinoic acid (RA) enhances Treg function and stability. However, it is unknown how RA receptor signaling in Tregs influences these processes in vivo. Herein, we employed mouse models in which RA signaling is silenced by the expression of the dominant negative receptor (DN) RARα in all T cells. Despite the fact that DNRARα conventional T cells are hypofunctional, Tregs had increased CD25 expression, STAT5 pathway activation, mTORC1 signaling and supersuppressor function. Furthermore, DNRARα Tregs had increased inhibitory molecule expression, amino acid transporter expression, and metabolic fitness and decreased antiapoptotic proteins. Supersuppressor function was observed when wild-type mice were treated with a pharmacologic pan-RAR antagonist. Unexpectedly, Treg-specific expression of DNRARα resulted in distinct phenotypes, such that a single allele of DNRARα in Tregs heightened their suppressive function, and biallelic expression led to loss of suppression and autoimmunity. The loss of Treg function was not cell intrinsic, as Tregs that developed in a noninflammatory milieu in chimeric mice reconstituted with DNRARα and wild-type bone marrow maintained the enhanced suppressive capacity. Fate mapping suggested that maintaining Treg stability in an inflammatory milieu requires RA signaling. Our findings indicate that RA signaling acts as a rheostat to balance Treg function in inflammatory and noninflammatory conditions in a dose-dependent manner.

Citing Articles

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells.

Chmiel J, Stasiak M, Skrzypkowska M, Samson L, Luczkiewicz P, Trzonkowski P Heliyon. 2024; 10(17):e36512.

PMID: 39319132 PMC: 11419861. DOI: 10.1016/j.heliyon.2024.e36512.


Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?.

Liu J, Zhang B, Zhang G, Shang D Front Immunol. 2024; 15:1345838.

PMID: 38449875 PMC: 10915070. DOI: 10.3389/fimmu.2024.1345838.


A novel retinoic acid drug, EYE-502, inhibits choroidal neovascularization by targeting endothelial cells and pericytes.

Shen Y, Xu M, Ren L, Li X, Han X, Cao X Sci Rep. 2023; 13(1):10439.

PMID: 37369771 PMC: 10300120. DOI: 10.1038/s41598-023-37619-7.


Regulatory T cells in the face of the intestinal microbiota.

Ramanan D, Pratama A, Zhu Y, Venezia O, Sassone-Corsi M, Chowdhary K Nat Rev Immunol. 2023; 23(11):749-762.

PMID: 37316560 DOI: 10.1038/s41577-023-00890-w.


Retinoic acid signaling in mouse retina endothelial cells is required for early angiogenic growth.

Como C, Cervantes C, Pawlikowski B, Siegenthaler J Differentiation. 2022; 130:16-27.

PMID: 36528974 PMC: 10006372. DOI: 10.1016/j.diff.2022.12.002.


References
1.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155(3):1151-64. View

2.
Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

3.
Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

4.
Romano M, Fanelli G, Albany C, Giganti G, Lombardi G . Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Front Immunol. 2019; 10:43. PMC: 6371029. DOI: 10.3389/fimmu.2019.00043. View

5.
Martelli M, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A . HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014; 124(4):638-44. DOI: 10.1182/blood-2014-03-564401. View